Castle Biosciences, Inc. (CSTL)
| Market Cap | 928.71M +119.6% |
| Revenue (ttm) | 357.28M +3.2% |
| Net Income | -19.42M |
| EPS | -0.65 |
| Shares Out | 30.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,196 |
| Open | 31.18 |
| Previous Close | 31.18 |
| Day's Range | 30.10 - 31.42 |
| 52-Week Range | 17.72 - 44.28 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+44.74%) |
| Earnings Date | Jul 30, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 44.74% from the latest price.
News
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares after “a strong Q2 beat” and another guidance…
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares. The company delivered a strong Q2 beat on…
Castle Biosciences price target raised to $57 from $52 at Lake Street
Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $57 from $52 and keeps a Buy rating on the shares following a Q2 “blowout” accompanied by a…
Castle Biosciences price target lowered to $36 from $43 at Baird
Baird lowered the firm’s price target on Castle Biosciences (CSTL) to $36 from $43 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Castle Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 20% year-over-year to $103.5 million, with strong volume growth in TissueCypher and DecisionDx-Melanoma. 2026 revenue guidance was raised to $365–$375 million, and positive adjusted EBITDA is expected for the remainder of 2026.
Castle Biosciences Earnings release: Q2 2026
Castle Biosciences released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Castle Biosciences Quarterly report: Q2 2026
Castle Biosciences has published its Q2 2026 quarterly earnings report on July 30, 2026.
Castle Biosciences Slides: Q2 2026
Castle Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Castle Biosciences reports Q2 EPS (7c), consensus (41c)
Reports Q2 revenue $103.5M, consensus $86.24M. “The Castle Biosciences (CSTL) team delivered another outstanding quarter,” said CEO Derek Maetzold. “We believe our strong growth through the first half...
Castle Biosciences raises 2026 revenue view to $365M-$375M from $345M-$355M
2026 consensus $352.29M. Sees positive adjusted EBITDA for 2026 and both Q3 and Q4.
Castle Biosciences Slides: Corporate presentation
Castle Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis FRIENDSWOOD, Texas, July 14, 2026...
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will rele...
Castle Biosciences’ i31-SLNB outperforms MIA nomogram in lymph node biopsy
Castle Biosciences (CSTL) announced the publication of a prospective, multicenter study in Dermatology and Therapy demonstrating that DecisionDx-Melanoma’s integrated sentinel lymph node biopsy test r...
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma In...
Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target The firm believes Castle should be owned for its quality revenue growth outlook over…
Castle Biosciences initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health thro...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15,...
Castle Biosciences’ TissueCypher Test surpasses 100,000 orders
Castle Biosciences (CSTL)’ TissueCypher Barrett’s Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient’s five-...
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled i...
Castle Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth in core diagnostic tests led to raised 2026 revenue guidance and robust margins. New product launches and pipeline innovations target dermatology and GI markets, while legislative trends and clinical value support future reimbursement and adoption.
Castle Biosciences price target lowered to $35 from $50 at KeyBanc
KeyBanc lowered the firm’s price target on Castle Biosciences (CSTL) to $35 from $50 and keeps an Overweight rating on the shares.
Castle Biosciences price target lowered to $40 from $50 at BTIG
BTIG lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The company delivered a solid 10% revenue beat…